Abstract
Early developments (National Cancer Institute Brochure, 1972; Rosenberg et al. [13, 14, 15]; pharmacology [1, 2, 4, 5, 7, 11, 18]) and animal tumor effectiveness ([7, 8, 12, 19, 20, 22]) have led to clinical programs [3, 16], Talley and O’Brien involving platinum derivatives. In personal communications (Schabel), discussions have centered around possible therapeutic potentiation of 5-FU by cis-platinum(II) diamminedichloride (PDD) in mouse L-1210 leukemia. As 5-FU was first synthesized and utilized clinically at the University of Wisconsin, much of our time has been spent in developing treatment modalities with 5-FU alone or in combination with other cytotoxic drugs. Certainly, we felt that potentiation of the tumoricidal action of 5-FU would not only benefit known responsive malignancies such as colon or breast adenocarcinomas, but could possibly induce increased activity towards minimally or previously unresponsive malignancies.
Keywords
- Chronic Lymphocytic Leukemia
- White Cell Count
- Single Daily Injection
- Platinum Coordination Complex
- Speech Discrimination Test
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Gale, G., Howle, J., Walker, E., Jr.: Antitumor and antimitogenic properties of cisdichloro(dipyridine)platinum(II). Cancer Res. 31, 950 (1971).
Harder, H., Rosenberg, B.: Inhibitory effects of anti-tumor platinum compounds on DNA, RNA, and protein synthesis in mammalian cells in vitro. Int. J. Cancer 6, 207 (1970).
Hill, J., Speer, R., Loeb, E., Maclellan, A., Hill, N., Khan, A.: Clinical experience with cis-platinum diamminedichloride, advances in antimicrobial and antineoplastic chemotherapy, Vol. 2, p. 255. München, Berlin, Wien: Urban and Schwarzenberg 1972.
Howle, J., Gale, G.: Cis-dichlorodiammineplatinum(II) - Persistent and selective inhibition of deoxyribonucleic acid synthesis in vivo. Biochem. Pharmacol. 19, 2757 (1970).
Howle, J., Thompson, H., Stone, A., Gale, G.: Cis-dichlorodiammineplatinum(II). Inhibition of nucleic acid synthesis in lymphocytes stimulated with phytohemagglutinin (35 675). Proc. Soc. exp. Biol. (N. Y.) 137, 820 (1971).
Kociba, R., Sleight, S.: Acute toxicologic and pathologic effects of cis-diamminedidlloroplatinum (NSC-119 875) in the male rat. Cancer Chemother. Rep. 55, 1 (1971).
Kociba, R., Sleight, S., Rosenberg, B.: Inhibition of dunning ascitic leukemia and Walker 256 carcinosarcoma with cis-diamminedidiloroplatinum (NSC-119 875). Cancer Chemother. Rep. 64, 325 (1970).
Leonard, B., Eccleston, E., Jones, D., Todd, P., Walpole, A.: Antileukemic and nephrotoxic properties of platinum compounds. Nature (Lond.) 234, 43 (1971).
Mackman, S., Ramirez, G., Ansfield, F.: Results of 5-fluorouracil (NSC-19 893) given by the multiple daily dose method in disseminated breast cancer. Cancer Chemother. Rep. 51, 483 (1967).
National Cancer Institute, Brochure on cis-platinum(II) diamminedichloride (NSC-119 875) 1972.
Roberts, J., Pascoe, J.: Cross-linking of complementary strands of DNA in mammalian cells by antitumor platinum compounds. Nature (Lond.) 235, 282 (1972).
Rosenberg, B., van Camp, L.: The successful regression of large solid sarcoma 180 tumors by platinum compounds. Cancer Res. 30, 1799 (1970).
Rosenberg, B., van Camp, L., Grimley, E., Thompson, A.: The inhibition of growth or cell division in Escherichia coli by different ionic species of platinum(IV) complexes. J. biol. Chem. 242, 1347 (1967).
Rosenberg, B., van Camp, L., Krigas, T.: Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature (Lond.) 205, 698 (1965).
Rosenberg, B., van Camp, L., Trosko, J., Mansour, V.: Platinum compounds: a new class of potent antitumor agents. Nature (Lond.) 222, 385 (1969).
Rossof, A., Slayton, R., Perlia, C.: Preliminary clinical experience with cis-diamminedichloroplatinum(II) (NSC-119 875, CACP). Cancer (Philad.) 30, 1451 (1972).
Schabel, F., Jr.: Unpublished data on combination chemotherapy of NSC-119 875 with NSC-19 893.
Shooter, K., Howse, R., Merrifield, R., Robins, A.: The interaction of platinum(II) compounds with bacteriophages T-7 and R-17. Chem.-Biol. Interactions 5, 289 (1972).
Sirica, A., Venditti, J., Kline, I.: Enhanced survival response of L-1210 leukemic mice. to a single combination treatment with cis-platinum(II) diamminedichloride (cis-Pt(II); NSC-119 875) plus cyclophosphamide (CY; NSC-26 271). Proc. Amer. Ass. Cancer Res. 12, 4 (1971).
Talley, R.: Chemotherapy of a mouse reticulum cell sarcoma with platinum salts. Proc. Amer. Ass. Cancer Res. 11, 78 (1970).
Talley, R., O’brien, R.: Personal communication.
Welsch, C.: Growth inhibition of rat mammary carcinoma induced by cis-platinum diamminedichloride(II). J. nat. Cancer Inst. 47, 1071 (1971).
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1974 Springer-Verlag Berlin · Heidelberg
About this chapter
Cite this chapter
Ellerby, R.A., Ansfield, F.J., Davis, H.L. (1974). Preliminary Report on Phase 1 Clinical Experience with Combined cis-diamminedichloride Platinum (II) (PDD) and 5-FU. In: Connors, T.A., Roberts, J.J. (eds) Platinum Coordination Complexes in Cancer Chemotherapy. Recent Results in Cancer Research, vol 48. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-49306-5_11
Download citation
DOI: https://doi.org/10.1007/978-3-642-49306-5_11
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-49308-9
Online ISBN: 978-3-642-49306-5
eBook Packages: Springer Book Archive